Department of Surgery, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea.
Department of Pathology, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea.
Ann Surg. 2023 Apr 1;277(4):e825-e831. doi: 10.1097/SLA.0000000000005355. Epub 2021 Dec 23.
We evaluated the prognostic value of tumor deposit (TD) counts and incorporated them with the number of positive lymph nodes to develop a revised nodal staging.
The current American Joint Committee on Cancer (AJCC) staging on colon cancer includes the TDs only for nodenegative patients, as N1c, and their counts are not considered.
We included consecutive patients with stage III colorectal cancer who underwent curative resections between January 2010 and December 2019. The patients were grouped as TD 0, TD 1, TD 2, or TD ≥3 based on their TD counts. Disease-free survival and overall survival were compared.
Of 2446 eligible stage III patients, 658 (26.9%) had TDs. Among them, 500 (76.0%) patients concurrently had positive lymph nodes (LNs). TD counts were significantly related to worse disease-free survival (DFS) and overall survival regardless of pT stages or the number of positive LNs. The patients were restaged based on the integrated number of TD counts and positive LNs. The N3 stage, which had ≥10 integrated TDs and positive LNs, was newly classified. Among the patients who completed 6 months of adjuvant chemotherapy, those upstaged to N2 from an initial stage of N1 experienced significantly worse DFS than those confirmed as N1 in the revised N staging. The newly N3-staged patients showed significantly worse DFS than the patients initially staged as N2.
Revised N staging using the integrated number of TD counts and positive LNs could predict DFS more accurately than current staging. It would also draw greater attention to the patients with high-risk stage III colon cancer staged as N3.
我们评估了肿瘤沉积(TD)计数的预后价值,并将其与阳性淋巴结数量相结合,以制定修订后的淋巴结分期。
目前的美国癌症联合委员会(AJCC)结肠癌分期仅将 TD 纳入阴性淋巴结(N1c)患者,且不计入其数量。
我们纳入了 2010 年 1 月至 2019 年 12 月期间接受根治性切除术的连续 III 期结直肠癌患者。根据 TD 计数,患者分为 TD0、TD1、TD2 或 TD≥3 组。比较无病生存率和总生存率。
在 2446 名符合条件的 III 期患者中,有 658 名(26.9%)存在 TD。其中,500 名(76.0%)患者同时存在阳性淋巴结(LNs)。无论 pT 分期或阳性 LNs 数量如何,TD 计数与较差的无病生存率(DFS)和总生存率均显著相关。根据 TD 计数和阳性 LNs 的综合数量对患者进行重新分期。新分类为 N3 期,即≥10 个综合 TD 和阳性 LNs。在完成 6 个月辅助化疗的患者中,从初始 N1 分期升级为 N2 的患者 DFS 明显差于修订 N 分期中确认为 N1 的患者。新分类为 N3 期的患者 DFS 明显差于初始分期为 N2 的患者。
使用 TD 计数和阳性 LNs 的综合数量进行修订后的 N 分期可以比当前分期更准确地预测 DFS。它还将使更多关注被分类为 N3 期的高危 III 期结肠癌患者。